Clinical validation Leverage Bondia and Microscape Technology as clinically validated, plant-derived microbiome solutions targeting bone health and inflammatory conditions to position as evidence-based medical foods in partnerships with healthcare providers, clinics, and nutraceutical distributors.

Strategic partnerships Explore collaborations with consumer health, nutrition, and specialty pharmacy channels, as well as contract research and manufacturing organizations, to accelerate product development, scale production, and expand reach into women’s health and inflammatory disease segments.

Key decision makers Target top-tier healthcare systems, osteoporosis clinics, rheumatology and endocrinology practices, and corporate wellness programs where there is a focus on gut–bone axis biology, enabling clinical adoption and reimbursement potential.

Funding signals Capitalize on recent strong funding and high-profile investor interest to approach strategic investors, large healthcare and food companies, and venture-backed firms seeking scalable microbiome-based medical foods with strong growth trajectories.

Global expansion Position Solarea Bio for international regulatory and market entry by highlighting plant-derived, microbiome-focused solutions that align with rising demand for non-pharmacologic, nutrition-based therapies in aging populations and autoimmune/inflammatory conditions.